Premium
Lung‐Targeted Rnai Therapeutics: Lung‐Endothelium‐Targeted Nanoparticles Based on a pH‐Sensitive Lipid and the GALA Peptide Enable Robust Gene Silencing and the Regression of Metastatic Lung Cancer (Adv. Funct. Mater. 18/2019)
Author(s) -
Abd Elwakil Mahmoud M.,
Khalil Ikramy A.,
Elewa Yaser H. A.,
Kusumoto Kenji,
Sato Yusuke,
Shobaki Nour,
Kon Yasuhiro,
Harashima Hideyoshi
Publication year - 2019
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201970121
Subject(s) - nanocarriers , gene knockdown , rna interference , gene silencing , small interfering rna , cancer research , lung cancer , materials science , lung , microbiology and biotechnology , biology , nanoparticle , nanotechnology , medicine , rna , gene , pathology , biochemistry
Engineering nanocarrier systems for efficient small interfering RNA (siRNA) delivery requires advanced materials that can achieve specific cellular targeting together with efficient intracellular trafficking for reaching target sites in the cytosol. In article number 1807677 , Ikramy A. Khalil, Hideyoshi Harashima, and co‐workers use nanoparticles modified with the GALA peptide as targeted therapy for the lung endothelium, resulting in a robust gene knockdown. The nanoparticles are successfully applied for the regression of metastatic lung cancer.